NCT00926523

Biomarkers in the Evaluation of Chronic Lung Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 67 (actual)
• Sponsor: Northwell Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.

Detailed description

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH. To study this hypothesis, we have two specific aims: 1. To evaluate plasma MIF concentration as a marker of severity in ILD and PH and 2. To determine the utility of breathe condensate analysis in the evaluation of ILD and PH. If we are successful in identifying MIF as a biomarker, it may identify MIF as a useful therapeutic target, as we have shown in other inflammatory disorders.

Conditions

• Pulmonary Hypertension
• Pulmonary Arterial Hypertension
• Interstitial Lung Disease

Interventions

Type	Name	Description
OTHER	Blood Gas	Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
OTHER	Pulmonary Exercise Test	Subject will ride exercise bike to assess their pulmonary function level.
OTHER	Spirometry	To assess subjects lung function
OTHER	Breath Condensate Collector	Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.

Timeline

• Start date: 2009-06-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2009-06-23
• Last updated: 2011-05-27

Locations

1 site across 1 country: United States